Yield10 Bioscience Announces Completion of Harvesting for 2020 Field Test Program to Evaluate Novel Yield and Compositional T...
October 01 2020 - 8:30AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience
company, today announced it has completed the harvest for its 2020
Field Test Program for Camelina and canola trials conducted in the
United States and Canada. Yield10’s 2020 Field Test Program is
designed to evaluate several novel traits in Camelina and canola,
and the Company expects to begin reporting data from the field
tests in the fourth quarter of 2020 through early 2021.
“We are pleased that our field trial contractors completed the
seed harvest on schedule at all of the sites involved in our 2020
Field Test Program,” said Dr. Kristi Snell, Ph.D., Chief Science
Officer of Yield10 Bioscience. “We will continue to work closely
with our field trial contractors to evaluate data collected from
our studies. These field tests are designed to generate agronomic,
yield and other data supporting the ongoing development of our
traits in Camelina, canola and other commercial crops.”
A summary of the 2020
Field Test Program:
-
Camelina/C3004:
C3004 is a trait designed to increase seed yield that has shown
promise in previous greenhouse and growth chamber experiments.
-
Camelina/CRISPR E3902: E3902 is a
CRISPR genome-edited trait designed to boost oil content. This line
demonstrated positive results in 2019 field tests.
- Camelina/CRISPR
C3007: C3007 is a CRISPR genome-edited trait designed to
boost oil content. This is the first season of field testing the
trait.
-
Camelina/C3014
and C3015:
Yield10 has designed a novel trait and reprogrammed Camelina to
produce a PHA biomaterial as a third seed product in addition to
the oil and protein meal.
- Canola/C3004:
C3004 is a trait designed to increase seed yield. This is the first
season of field testing the trait in canola.
- Canola/C3003:
Yield10 grew 14 new canola/C3003 commercial quality lines for seed
bulk up in the field in 2020 that the Company currently plans to
field test in 2021. C3003 is a seed yield trait.
In the field tests of its novel traits in Camelina and canola,
Yield10 monitored key agronomic and growth parameters of the plants
throughout the growth period. Yield10 also plans to evaluate seed
yield, oil content, PHA content and/or other metrics of the traits
as appropriate after seed harvest. The field tests are designed to
generate data on the performance of the novel traits under field
conditions and to advance the development of the traits toward
commercialization. The program will also generate field grown seed
for subsequent field studies.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
developing crop innovations for sustainable global food security.
The Company uses its “Trait Factory” including the “GRAIN” big data
mining trait gene discovery tool as well as the Camelina oilseed
“Fast Field Testing” system to develop high value seed traits for
the agriculture and food industries. As a path toward
commercialization of novel traits, Yield10 is pursuing a partnering
approach with major agricultural companies to drive new traits into
development for canola, soybean, corn, and other commercial crops.
The Company is also developing improved Camelina varieties as a
platform crop for the production and commercialization of
nutritional oils, proteins, and PHA biomaterials. The Company’s
expertise in oilseed crops also extends into canola, where it is
currently field-testing novel yield traits to generate data to
drive additional licensing opportunities. Yield10 is headquartered
in Woburn, MA and has an Oilseeds Center of Excellence in
Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn. (YTEN-G)
Safe Harbor for
Forward-Looking
Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, statements regarding the results and outcome of, and
information gathered from the field tests, the ability to use the
results of the tests in future studies or licensing activities,
whether the company’s traits will increase seed yield, boost oil
content and/or produce PHA biomaterial, and expectations with
regard to the timing of reporting results of the field tests or
additional field testing, constitute forward-looking statements.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including the risks and
uncertainties detailed in Yield10 Bioscience's filings with the
Securities and Exchange Commission. Yield10 assumes no obligation
to update any forward-looking information contained in this press
release or with respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Sep 2023 to Sep 2024